Literature DB >> 30803972

Comparison of the Antiviral Activity of Bictegravir against HIV-1 and HIV-2 Isolates and Integrase Inhibitor-Resistant HIV-2 Mutants.

Robert A Smith1, Dana N Raugi2, Vincent H Wu2, Christopher G Zavala2, Jennifer Song2, Khardiata Mbaye Diallo3, Moussa Seydi3, Geoffrey S Gottlieb2,4.   

Abstract

We compared the activity of the integrase inhibitor bictegravir against HIV-1 and HIV-2 using a culture-based, single-cycle assay. Values of 50% effective concentrations ranged from 1.2 to 2.5 nM for 9 HIV-1 isolates and 1.4 to 5.6 nM for 15 HIV-2 isolates. HIV-2 integrase mutants G140S/Q148R and G140S/Q148H were 34- and 110-fold resistant to bictegravir, respectively; other resistance-associated mutations conferred ≤5-fold changes in bictegravir susceptibility. Our findings indicate that bictegravir-based antiretroviral therapy should be evaluated in HIV-2-infected individuals.
Copyright © 2019 American Society for Microbiology.

Entities:  

Keywords:  HIV treatment; HIV-2; West Africa; antiretroviral therapy; bictegravir; drug resistance; human immunodeficiency virus; integrase

Mesh：

Substances：

Year:  2019        PMID： 30803972      PMCID： PMC6496081          DOI： 10.1128/AAC.00014-19

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  62 in total

1.  Dolutegravir for the treatment of HIV-2 infection.

Authors:  Ana Treviño; Teresa Cabezas; Ana Belén Lozano; Rosa García-Delgado; Luis Force; José María Fernández-Montero; Carmen de Mendoza; Estrella Caballero; Vincent Soriano
Journal:  J Clin Virol       Date:  2015-01-05       Impact factor: 3.168

Review 2.  Antiretroviral drug resistance in human immunodeficiency virus type 2.

Authors:  Michel L Ntemgwa; Thomas d'Aquin Toni; Bluma G Brenner; Ricardo J Camacho; Mark A Wainberg
Journal:  Antimicrob Agents Chemother       Date:  2009-05-26       Impact factor: 5.191

3.  Antiviral Activity of Bictegravir and Cabotegravir against Integrase Inhibitor-Resistant SIVmac239 and HIV-1.

Authors:  Said A Hassounah; Ahmad Alikhani; Maureen Oliveira; Simrat Bharaj; Ruxandra-Ilinca Ibanescu; Nathan Osman; Hong-Tao Xu; Bluma G Brenner; Thibault Mesplède; Mark A Wainberg
Journal:  Antimicrob Agents Chemother       Date:  2017-11-22       Impact factor: 5.191

4.  The role of raltegravir in the treatment of HIV-2 infections: evidence from a case series.

Authors:  Kevin Peterson; Jean Ruelle; Marc Vekemans; Frederick P Siegal; Jane R Deayton; Robert Colebunders
Journal:  Antivir Ther       Date:  2012-08-15

5.  A comparison of HIV-1 and HIV-2 infections in hospitalized patients in Abidjan, Côte d'Ivoire.

Authors:  K M De Cock; K Odehouri; R L Colebunders; G Adjorlolo; M F Lafontaine; A Porter; E Gnaore; L Diaby; J Moreau; W L Heyward
Journal:  AIDS       Date:  1990-05       Impact factor: 4.177

6.  Plasma viral load in HIV-1 and HIV-2 singly and dually infected individuals in Guinea-Bissau, West Africa: significantly lower plasma virus set point in HIV-2 infection than in HIV-1 infection.

Authors:  S Andersson; H Norrgren; Z da Silva; A Biague; S Bamba; S Kwok; C Christopherson; G Biberfeld; J Albert
Journal:  Arch Intern Med       Date:  2000-11-27

7.  Human immunodeficiency virus types 1 and 2 exhibit comparable sensitivities to Zidovudine and other nucleoside analog inhibitors in vitro.

Authors:  Robert A Smith; Geoffrey S Gottlieb; Donovan J Anderson; Crystal L Pyrak; Bradley D Preston
Journal:  Antimicrob Agents Chemother       Date:  2007-10-29       Impact factor: 5.191

8.  Accumulation of Multiple Mutations In Vivo Confers Cross-Resistance to New and Existing Integrase Inhibitors.

Authors:  Wendy W Zhang; Peter K Cheung; Natalia Oliveira; Marjorie A Robbins; P Richard Harrigan; Aniqa Shahid
Journal:  J Infect Dis       Date:  2018-10-20       Impact factor: 5.226

9.  HIV-2 integrase polymorphisms and longitudinal genotypic analysis of HIV-2 infected patients failing a raltegravir-containing regimen.

Authors:  Joana Cavaco-Silva; Ana Abecasis; Ana Cláudia Miranda; José Poças; Jorge Narciso; Maria João Águas; Fernando Maltez; Isabel Almeida; Isabel Germano; António Diniz; Maria de Fátima Gonçalves; Perpétua Gomes; Celso Cunha; Ricardo Jorge Camacho
Journal:  PLoS One       Date:  2014-03-28       Impact factor: 3.240

Review 10.  HIV-2: the forgotten AIDS virus.

Authors:  Thushan I de Silva; Matthew Cotten; Sarah L Rowland-Jones
Journal:  Trends Microbiol       Date:  2008-10-27       Impact factor: 17.079
View more
  3 in total

1.  Spectrum of Activity of Raltegravir and Dolutegravir Against Novel Treatment-Associated Mutations in HIV-2 Integrase: A Phenotypic Analysis Using an Expanded Panel of Site-Directed Mutants.

Authors:  Robert A Smith; Vincent H Wu; Jennifer Song; Dana N Raugi; Khardiata Diallo Mbaye; Moussa Seydi; Geoffrey S Gottlieb
Journal:  J Infect Dis       Date:  2022-08-26       Impact factor: 7.759

2.  Long Dissociation of Bictegravir from HIV-1 Integrase-DNA Complexes.

Authors:  Kirsten L White; Nathan Osman; Ernesto Cuadra-Foy; Bluma G Brenner; Devleena Shivakumar; Federico Campigotto; Manuel Tsiang; Philip A Morganelli; Nikolai Novikov; Scott E Lazerwith; Haolun Jin; Anita Niedziela-Majka
Journal:  Antimicrob Agents Chemother       Date:  2021-03-01       Impact factor: 5.191

3.  Brief Report: Bictegravir/Emtricitabine/Tenofovir Alafenamide Efficacy in Participants With Preexisting Primary Integrase Inhibitor Resistance Through 48 Weeks of Phase 3 Clinical Trials.

Authors:  Michelle L D'Antoni; Kristen Andreatta; Rima Acosta; Hal Martin; Silvia Chang; Ross Martin; Kirsten L White
Journal:  J Acquir Immune Defic Syndr       Date:  2022-04-01       Impact factor: 3.771
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.